Mass General Brigham Ventures is an early-stage venture capital firm founded in 2008 to advance new life science technologies emerging from Mass General Brigham's extensive research network. Leveraging a unique model that combines first access and proprietary rights to disruptive deal flow with an established track record of new venture formation, company building, and value creation, the firm invests in bold, transformative innovations to develop new drugs and technologies aimed at improving patient outcomes worldwide.